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Abstract 
Background. Tattooing is a widespread phenomenon, with an estimated prevalence of 10–30% in 
Western populations. For psoriasis patients, current recommendations are to avoid having a tattoo 
if the disease is active and they are receiving immunosuppressive treatments. Although scientific 
data supporting these recommendations is lacking, dermatologists are often reluctant to advocate 
tattooing in psoriasis patients. 
Objective. We aimed to evaluate the frequency of tattoo complications in patients with psoriasis 
and determine if the occurrence of complications was associated with psoriasis status and 
treatments received at the time of tattooing.
Methods. We performed a multicentre cross-sectional study. Adults with psoriasis were 
consecutively included and classified as tattooed or non-tattooed. Prevalence of complications 
associated with tattoos was then evaluated according to psoriasis onset and treatments. The study 
was divided into three parts, in which data were collected through a series of questionnaires filled 
in by the dermatologist. Complications included pruritus, oedema, allergic reaction/eczema, 
infection/superinfection, granuloma, lichenification, photosensitivity, Koebner phenomenon and 
psoriasis flare after tattooing. Diagnosis of complications was made retrospectively.
Results. We included 2053 psoriatic patients, 20.2% had 894 tattoos. Amongst non-tattooed 
patients, 15.4% had wished to be tattooed, with psoriasis being stated as a reason for not having a 
tattoo by 44.0% and 5.7% indicating that they planned to have a tattoo in the future. Local 
complications, such as oedema, pruritus, allergy and Koebner phenomenon were reported in 
tattoos in 6.6%, most frequently in patients with psoriasis requiring treatment at the time of 
tattooing (p<0.0001). No severe complications were reported.
Conclusions. The rate of tattoo complications in psoriasis patients was low. Although the risk of 
complications was highest amongst patients with psoriasis requiring treatment at the time of 
tattooing, all the complications observed were benign. These results can be helpful for practitioners 
to give objective information to patients.
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Introduction
Tattooing is defined as the introduction of exogenous pigments or dyes into the dermis to 
permanently mark the body in an artistic way. It has become a widespread phenomenon, especially 
amongst young people, with the current prevalence estimated at 10–30% in Western countries1,2. 
In France, 17% of the adult population are reported to have at least one tattoo3. However, the 
tattooing procedure is known to be associated with potential complications, such as pruritus, 
swelling, photosensitivity, infections and allergies4-6.
Patients with chronic dermatoses, such as psoriasis, may also be interested in having a tattoo. 
According to a recent French study, 5.4% of tattooed people had psoriasis3. Psoriasis is not a strict 
contraindication for tattooing, but there are controversies about the advisability of receiving a 
tattoo if the disease is active and if patients are receiving immunosuppressive treatments7. There is 
a lack of clarity in the scientific literature about the risk of complications related to tattooing in 
this population. Koebner phenomenon has been reported on tattoo sites in several case reports and 
in one case series of patients with psoriasis8. However, no severe complications after tattooing, 
such as infections in patients undergoing immunosuppressive therapies, have been reported. 
To evaluate the risks of tattooing in psoriatic patients, the French national network and 
multicentre study group for research on psoriasis (GEM Resopso: http://www.resopso.fr/la-
recherche/) developed a two-part clinical research project named “Tatou”. During the first phase 
of this project, we conducted an international study in France, Italy and Finland to evaluate how 
dermatologists address the issue of tattoos in patients with psoriasis in clinical practice9. Our study 
revealed that 52.6% of dermatologists were reluctant to advocate tattooing in patients with 
psoriasis and 88.5% considered that tattoos could cause problems in these patients. Furthermore, 
81.0% of dermatologists were opposed to tattooing in patients with active psoriasis, and 49.2% 
were opposed in patients with psoriasis in complete remission. However, less than a quarter of 
these dermatologists had personal experience of complications arising with a tattoo in a patient 
with psoriasis. For those who had encountered patients with complications, the complications were 
mild and easily treatable. The dermatologists included in our study were most likely to be reluctant 
to advocate tattooing in patients undergoing immunosuppressive treatments or in those receiving 
phototherapy. 
Thus, the first part of our study revealed a widespread reluctance amongst dermatologists to 
advocate tattooing in patients with psoriasis, despite a lack of scientific data on this subject. Here, A
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we report the results of the second phase of the “Tatou” project in which we evaluated the 
frequency of complications after tattooing in patients with psoriasis. We also investigated whether 
the occurrence of these complications varied depending on the psoriasis status and type of 
psoriasis treatment the patients were receiving at the time the tattooing was performed. 
This article is protected by copyright. All rights reserved
Materials and methods
Study design, setting and participants
This multicentre, cross-sectional observational study was conducted in France by dermatologists 
practising in 23 centres located within university (n=7), general (n=11) or military (n=1) hospitals, 
or within private clinics (n=4). All dermatologists participating in the study were members of the 
GEM Resopso and were asked to include consecutive adult patients (> 18 years) with psoriasis 
attending their centres between April to August 2018. 
The study was conducted in accordance with the good clinical practice guidelines. The 
research protocol was approved by the local ethics committee (Comité de Protection des 
Personnes Sud-Est I – Saint-Etienne – ref: 2018-22). 
Assessment outcomes 
The main study outcomes were determination of prevalence and type of complications associated 
with tattoos. We then evaluated whether occurrence of these complications was associated with 
psoriasis status and type of psoriasis treatments. 
Other study outcomes were determination of frequency and number of tattoos, identification 
of demographic and clinical characteristics associated with the likelihood of having a tattoo, and 
reasons for patients abstaining from having a tattoo. 
Assessment methods 
All study assessments were carried out during the recruitment consultation and data were collected 
through a series of questionnaires filled in by the dermatologist. 
Patients were first asked whether or not they had a tattoo (1st part of the whole study). 
Patients with tattoos and permanent makeup were both considered as being tattooed. Patients 
without tattoo were then asked if they had ever wanted a tattoo, if they were planning to have one 
and why they had never had one.
The dermatologist then filled in two further questionnaires for tattooed patients. The first 
questionnaire (2nd part of the whole study) included items about patient demographics, medical 
history, number of tattoos and psoriasis characteristics (age of onset, type, family history, 
association with psoriatic arthritis, disease severity and specific treatments received). The second 
questionnaire (3rd part of the whole study) concerned patients’ tattoos, with each tattoo being A
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analysed separately. The data were evaluated with the patient and included the date when the 
tattooing was carried out; its localisation, size and colour(s); occurrence of any complications (e.g. 
Koebner phenomenon, infection or allergy); and psoriasis treatments at time of the tattooing.
Data obtained from these questionnaires were used to classify patients into groups, as 
tattooed or not tattooed. The tattooed patients were then classified into three groups: tattooing 
carried out before psoriasis onset; tattooing carried out after psoriasis onset in the absence of 
psoriasis treatment (psoriasis without treatment group), and tattooing carried out after psoriasis 
onset whilst the patient was undergoing psoriasis treatment (the psoriasis with treatment group). If 
a patient had two or more tattoos, then this patient could have tattoos classified in multiple groups. 
Definition of complications
Diagnosis of complications was made retrospectively. We tried to define precisely each 
complication in order to match it to to each diagnosis. We asked the patients if diagnosis was 
confirmed by a dermatologist and if there was a skin biopsy. Complications of the tattoo were 
classified as following:
- pruritus was defined as itch without skin change,
- oedema was defined as transient swelling with or without itch, without erythema on the 
tattoo, 
- allergic reaction – eczema were defined as itchy and inflamed patches of skin within one 
colour of the tattoo. We insist on the short delay after tattooing (1-7 days) and the effect of 
corticosteroids if used. Late onset allergic reactions were not taken into account,
- infection/superinfection were defined as: 1) early superinfection as an impetigo or 
cellulitis. We enquired for the necessity of topical or general antibiotics to control the 
disease; 2) or later superinfection such as mycobacterial infection; this infection needed 
bacterial confirmation to be included in the study,
- granuloma (included sarcoidosis) and lichenification needed histological diagnosis. 
Granuloma was defined as a collection of inflammatory cells which includes histiocytes 
(macrophages, epithelioid and/or giant multinucleated cells), and lymphocytes,
- photosensitivity was defined as occurrence of symptoms such as local itch in the tattoo 
directly after a variable time of unprotected sun exposure,
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- Koebner phenomenon was defined as appearance of psoriasis strictly located at the tattoo 
lines either just after tattooing, or later. In the definition we also included well-delineated 
psoriasis plaques in tattoo fields,
- psoriasis flare after tattoo was defined as psoriasis flare during the 2 weeks after tattooing, 
in the area of the tattoo, and also general flare, including psoriasis arthritis
Statistical analysis 
The size of the study population was determined using data from previous studies indicating that 
15–20% of adults in France have a tattoo1,3. To obtain statistically relevant results, we aimed to 
include at least 2000 psoriatic patients, 400 of whom we would have expected to be tattooed. 
Quantitative data are expressed as the mean ± standard deviation (SD) and qualitative data 
as the number and percentage of patients or tattoos. Means were compared using the Student t-test 
and frequencies were compared using the Chi square test or Fisher exact test, as appropriate. A p-
value of less than 0.05 was considered statistically significant. Multiple logistic regression analysis 
was carried out to evaluate the relationship between being tattooed and gender, age, and age at 
onset of psoriasis (p-value < 0.10 in univariate analysis). Statistical analyses were performed using 
R software version 3.0.2 (http://www.r-project.org).
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Results
Patient demographics 
During the 5-month period, 2053 psoriatic patients were included in our study, 414 (20.2%) were 
tattooed (Table 1) and 1639 were non-tattooed (79.8%). Univariate analysis revealed that tattooed 
patients were more likely to be female (p=0.03), younger (p<0.0001), and have an earlier age 
psoriasis onset (p<0.0001) than non-tattooed patients (Table 1). After multivariate analysis, only 
age was found to be linked to the likelihood of having a tattoo: p<0.0001, with an odds ratio (OR) 
= 0.97 and 95% confidence interval (CI) of 0.96–0.98 (Table 1). 
Non-tattooed patients 
A summary of the responses given by non-tattooed patients about their reasons for not having a 
tattoo is provided in Table 2. Among patients without tattoos, 252 (15.4%) had wished to have a 
tattoo but never received one. Amongst these patients, 111 (44.0%) did not have a tattoo because 
of their psoriasis, because of the treatment for their psoriasis, or due to negative advice from their 
doctor. Finally, 93 of the non-tattooed patients (5.7%) planned to have a tattoo in the future.
Demographic and clinical characteristics of tattooed patients
In patients under the age of 50, women were more often tattooed than men (Figure 1). Tattooing 
was most common in patients in the 25–34 year-old age group and was least common in patients 
aged 65 and over (Figure 1).
The characteristics of the psoriasis in the 414 tattooed patients are detailed in Table 3: 
plaque psoriasis was the most common form of psoriasis (n=300; 72.5%), and 79 patients (19.1%) 
had associated psoriatic arthritis. Before inclusion, the most common treatments were 
methotrexate (n=194; 46.9%), phototherapy (n=158; 38.2%), adalimumab (n=95; 22.9%), 
ustekinumab (n=90; 21.7%), and acitretin (n=85; 20.5%).
Tattoo characteristics and treatments at the time of tattooing
Tattoo characteristics, and details of the psoriasis status of the patients and treatments they were 
receiving at the time they were tattooed are shown in Table 4. There were 894 tattoos, with a mean 
of 2.2 tattoos per patient and a range of one to 13 tattoos per patient. The majority of tattoos were 
black (n=688; 77.0%), most commonly located on the upper limb (n=530; 59.3%), and covered A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
less than 5% of the body surface area (n=851; 95.2%). Tattooing was carried out in 336 patients 
(38.3%) before psoriasis onset, and in 542 (61.7%) after psoriasis developed. Among these, 344 
(38.3) were tattooed in an episode without treatment for psoriasis at the time of tattooing, and 198 
(22.6%) had a tattoo whilst receiving treatment for psoriasis: 72 patients (8.1%) were receiving 
local steroids, 56 (6.3%) systemic treatments, and 67 (7.5%) biotherapy at the time of tattooing. 
Local complications associated with tattoos according to psoriasis and treatment status 
Local complications were reported for 58 of the 894 tattoos (6.6%; Table 5). There was oedema in 
2.1%, isolated pruritus in 2.7%, allergy in 0.2%, local infection in 0.7% and Koebner phenomenon 
in 3.0%. Complications occurred most frequently in the psoriasis with treatment group (p<0.0001; 
Table 5), with oedema (p=0.049), pruritus (p<0.0001), allergy (p=0.03), and Koebner 
phenomenon (Fig. 2) (p<0.0001) all being more common in the psoriasis with treatment group. 
There were no differences in the frequency of complications between the group before psoriasis 
onset and the group with psoriasis without treatment (Table 5).
Tattooing caused psoriasis flare in 29 cases (3.2%) independently of the occurrence of 
Koebner phenomenon. Tattooing as a cause for psoriasis flare was most frequent in the psoriasis 
with treatment group (p=0.0002). Tattooing caused psoriatic arthritis flare in three cases (0.3%; 
Table 5). 
During a psoriasis flare-up, psoriasis plaques occurred within the tattooed area (Fig. 3) in 
177 tattoos (19.8%), most commonly in the psoriasis with treatment group (p<0.0001) and 
regardless of the treatment received. Tattoos were spared by psoriasis in 417 cases (46.7%; Table 
5).
Amongst patients in the psoriasis with treatment group, the occurrence of local 
complications appeared to be more common in patients undergoing systemic treatment or 
biotherapy (p=0.03) at the time of tattooing than in those receiving local treatments; however, no 
statistical differences in the frequency of complications were observed between the treatment 
subgroups (Table 6).
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Discussion
Our multicentre, cross-sectional observational study provided needed information about the 
frequency of complications occurring after tattooing in psoriasis patients, and on the difference in 
frequency according to psoriatic treatments. 
We found that tattoos were more frequent in younger patients, notably within the 25–34 
year-old age group. These demographic trends, identified in our population of psoriasis patients, 
were in accordance with those observed by Kluger et al. 3 in the general population in France.
Amongst our non-tattooed patients, 15.4% indicated that they had wanted a tattoo. For 
44.0% of these patients, their disease and the negative advice from their physician had prevented 
them from undergoing the tattooing procedure. These findings are similar to those of a Finnish 
study of tattooing and psoriasis in 90 patients, in which 28% of non-tattooed patients indicated that 
fear of a worsening of their psoriasis had prevented them from receiving a tattoo10. The 
characteristics of the tattoos in our study population were broadly similar to those reported in 
previous studies11-13, with our study revealing a predominance of monochrome (black) tattoos, 
located on the upper limb and trunk and a mean of 2.2 tattoos per patient. However, the total 
tattooed area per person was larger in our study than that reported previously: the tattoos in our 
study most frequently covered between 1 and 5% of the body surface area, whereas in the study by 
Høgsberg et al. they most commonly covered between 0.1 and 1%11.
We found that the rate of local complications occurring in our study population was low, at 
only 6.6%. We also found that tattooing induced psoriasis flares in 3.5% of cases, including 
psoriasis arthritis. The complication rates after tattooing reported in the literature are extremely 
variable, ranging from 2.1 to 67.5% and depending of the methodology: prospective studies, self-
reported declaration, delay of analysis, … 4,5,12-16. Kluger et al. found that minor symptoms – such 
as onset of pruritus and oedema more than three months after tattooing – were frequent (20%), but 
that persistent and chronic reactions after tattooing were rare, occurring in less than one out of 10 
individuals14. The rates of 2.1% for oedema, 2.7% for pruritus, 0.2% for allergies and 0.7% for 
infections observed in our study are similar to those reported in the general population in a recent 
French study 3. However, the complication rates in our psoriasis population were much lower than 
those reported in the general population by other studies.4,13,15,16. The majority of tattoos in our 
study were monochrome. Thus, the very low rate of allergies occurring in our study could be 
explained by the fact that allergies are generally more common with coloured tattoos, especially A
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red ones4,13,14. Also, we did not take into account late onset allergies, which could explain this low 
percentage. Moreover, as the definition of complications was retrospective, often made on patient 
descriptions, we cannot exclude misclassifications of some diagnoses. 
No photosensitivity reactions, granulomas, lichenoid reactions or cancers were reported in 
our study, despite explicit questions about these complications being included in the questionnaire. 
Photosensitivity reactions on tattoos seem to be frequent according to previous studies. In a beach 
study in Denmark involving 144 tattooed participants17, the rate of complications was 42%, with 
52% of the complications being due to sun exposure. Similarly, in the study by Høgsberg et al., 
photosensitivity was reported in 9% of tattoos with 58% of complaints about tattoos being caused 
by sun exposure11. 
In our study, the rate of Koebner phenomenon was only 3.0%, and that of tattoos causing 
psoriasis flare only 3.2%. These rates are much lower than those reported by Kluger et al. in their 
study of tattooing in 90 psoriatic patients10, where the rate of Koebner phenomenon was 28%, that 
of psoriasis flare-ups after tattooing was 30%, and that of flare-ups on another part of the body 
was 7%. In the first part of our “Tatou” study concerning dermatologists’ opinions about tattooing 
in psoriatic patients, 15% of dermatologists reported that the Koebner phenomenon had occurred 
after tattooing in psoriatic patients9. Our findings from the current study show that the Koebner 
phenomenon was more common in the psoriasis with treatment group, with a rate of 9.1%. The 
higher frequency amongst patients in this group might be explained by the fact that patients under 
systemic treatment or biotherapy have more severe psoriasis and therefore have a higher risk of 
developing the Koebner phenomenon. 
We also found that local complications were most frequent in the psoriasis with treatment 
group, in particular amongst patients treated with biotherapies. Indeed, this increase in 
complications may be associated either with the severity of the psoriasis or with the treatments 
received. Patients in our study had mean Psoriasis Area and Severity Index (PASI) and 
Dermatology Life Quality Index (DLQI) scores indicative of severe psoriasis. Interestingly, a few 
case reports have been published concerning tattoo complications in patients undergoing systemic 
treatments. For example, delayed healing, fatigue and local infection were reported in a 27-year-
old woman with ankylosing spondylitis treated with adalimumab and methotrexate, and delayed 
healing and the Koebner phenomenon were reported in a 29-year-old woman treated with 
infliximab for psoriasis 18. Delayed healing was also reported in a 19-year-old woman treated with A
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isotretinoin for acne 19. Finally, a granulomatous reaction was reported in a 39-year-old man 
undergoing etanercept treatment for ankylosing spondylitis 20.
The main limitation of our study was memory bias, which could partly explain why the 
prevalence of complications in our study was lower than that found in previous reports. Other 
limitations were the fact that the diagnosis was made retrospectively and that the severity and 
duration of the complications were not included. The strengths of our study were the large number 
of participants and the multicentre approach.
In conclusion, we found that the overall complication rate in psoriasis patients after tattooing was 
low, but that complications were most likely in patients who underwent tattooing after psoriasis 
onset and whilst undergoing treatment. However, even in patients with psoriasis requiring 
treatment, the complications we observed were benign. The Koebner phenomenon, which is often 
easily treatable and transient, was the most frequent complication amongst these patients. 
Dermatologists and healthcare professionals should be mindful of the fact that tattooing is a way 
for psoriasis patients to express themselves, and can have positive effects through improving 
wellbeing and self-esteem. Our study provides valuable objective information about the risks 
associated with tattooing in this population. This information should be used by dermatologists 
and general practitioners to help patients decide if they want to be tattooed or not.
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Table 1. Demographic data for the whole study population and according to the presence or absence of tattoos. 
Tattoo
Univariate 
analysis
Multivariate
analysis
All patients
N=2053
Yes (n=414) No (n=1639) p-value p-value OR [95% CI]
Gender
Female 915 (44.6) 204 (22.3) 711 (77.7) 0.03 0.07 0.82 [0.66–1.02]
Male 1138 (55.4) 210 (18.5) 928 (81.5)
Age (years) 50.3 ± 15.3 44.5 ± 12.4 51.9 ± 15.5 < 0.0001 < 0.0001 0.97 [0.96–0.98]
Age at onset of psoriasis (years) 29.9 ± 16.5 26.3 ± 13.4 30.9 ± 17.1 < 0.0001 0.99 1.00 [0.99–1.01]
Quantitative data are expressed as means ± standard deviation and qualitative data as the number of patients, n (%). OR, odds ratio; CI, confidence 
interval
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Table 2. Non-tattooed patients, n=1639
Have you ever wanted a tattoo? Yes 252 (15.4)
Why didn’t you do it? n=252 a
For personal or familial reasons 
Because of my psoriasis b
Because of my treatments b
My practitioner gave negative advice b
Other reasons
71 (28.2)
108 (42.9)
8 (3.2)
2 (0.8)
69 (27.4)
Do you wish to be tattooed in the future? Yes 93 (5.7)
Qualitative data are expressed as the number of patients, n (%).a Patients could provide multiple 
explanations. b These three responses were included in the group “because of psoriasis and/or 
negative advice from practitioner” 
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Table 3. Psoriasis characteristics of tattooed patients.
n=414
Family history of psoriasis 178 (43.0)
Plaque psoriasis 300 (72.5)
Psoriatic arthritis 79 (19.1)
Peak severity of psoriasis  
PASI a 13.1 ± 10.6
BSA (%) a 24.1 ± 23.0
DLQI 11.3 ± 7.8
Treatments before or at inclusion
Phototherapy 158 (38.2)
Systemic treatments
Acitretin 85 (20.5)
Alitretinoin 1 (0.2)
Methotrexate 194 (46.9)
Cyclosporin 97 (23.4)
Apremilast 49 (11.8)
Biotherapies
Efalizumab 7 (1.7)
Etanercept 40 (9.7)
Adalimumab 95 (22.9)
Infliximab 15 (3.6)
Guselkumab 3 (0.7)
Golimumab 1 (0.2)
Ustekinumab 90 (21.7)
Secukinumab 35 (8.5)
Ixekizumab 19 (4.6)
Brodalumab 2 (0.5)
Quantitative data are expressed as the mean ± standard deviation and qualitative data as the 
number of patients, n (%). PASI: Psoriasis Area Severity Index; BSA: Body Surface Area; DLQI: 
Dermatology Life Quality Index. a Assessments for plaque psoriasis only.A
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Table 4. Tattoo characteristics 
N=894 a
Number of tattoos per patient 2.2 ± 1.8
Location
Upper limb 
Lower limb
Trunk
Face
Neck
n=886 a
530 (59.3)
118 (13.2)
170 (19.0)
28 (3.1)
40 (4.5)
Body surface area b
< 1%
1–5%
5–10%
> 10%
n=882 a
251 (28.1)
600 (67.1)
27 (3.0)
4 (0.4)
Monochrome (black) 688 (77.0)
Timing of the tattoo procedure 
before psoriasis developed
after psoriasis developed, without treatment
after psoriasis developed, with treatment
n=878 a
336 (38.3)
344 (39.2)
198 (22.6)
Treatments at the time of tattooing n=891 a
Local steroids or vitamin D analogues 72 (8.1)
Systemic treatments
Phototherapy
56 (6.3)
12 (1.3)
Acitretin 3 (0.3)
Cyclosporin 10 (1.1)
Azathioprine 1 (0.1)
Steroids 1 (0.1)
Methotrexate 27 (3.0)
Apremilast 1 (0.1)
Apremilast + methotrexate 1 (0.1)
Biotherapies 67 (7.5)A
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Anti-TNF alpha 28 (3.1)
Etanercept 4 (0.4)
Adalimumab 22 (2.5)
Infliximab 2 (0.2)
IL-12/23 inhibitor 35 (3.9)
Ustekinumab 35 (3.9)
IL-17 inhibitors 4 (0.4)
Secukinumab 1 (0.1)
Ixekizumab 3 (0.3)
Quantitative data are expressed as the means ± standard deviation and qualitative data as number 
of tattoos, n (%). TNF, tumour necrosis factor; IL, interleukin. a Number of tattoos evaluated. b BSA of 
the tattoo was defined as follow: 1% of BSA corresponded to one palm of the patient. We considered the 
outer perimeter of the tattoo, even if the inner part was not tattooed.
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Table 5. The frequency of local complications associated with tattoos according to psoriasis and treatment status
Tattoo after psoriasis onset
All 
tattoos
N=894 a
Tattoo before 
psoriasis onset
n=336
without 
treatment
 n=344
with treatment
n=198 p-value
Local complications 58 (6.6) 10 (3.0) 20 (5.8) 28 (14.1) <0.0001
Oedema 19 (2.1) 5 (1.5) 5 (1.5) 9 (4.5) 0.049
Isolated pruritus 24 (2.7) 3 (0.9) 7 (2.0) 14 (7.1) <0.0001
Allergy 2 (0.2) 0 (0) 0 (0) 2 (1.0) 0.03
Local infection 6 (0.7) 2 (0.6) 2 (0.6) 2 (1.0) 0.76
Koebner phenomenon (Fig. 2) 26 (3.0) 1 (0.3) 7 (2.0) 18 (9.1) <0.0001
Psoriasis flare after tattoo
Cutaneous psoriasis 29 (3.2) 3 (0.9) 11 (3.2) 15 (7.6) 0.0002
Psoriatic arthritis 3 (0.3) 1 (0.3) 2 (0.6) 0 (0) 0.53
Presence of psoriasis plaques within the tattoo 
during a flare of the disease b
Psoriatic plaques within the tattoo (Fig. 3) 177 (19.8) 40 (11.9) 76 (22.1) 60 (30.3) < 0.0001
Tattoos spared by psoriasis 417 (46.7) 169 (50.6) 158 (46.5) 80 (40.4) 0.07
Qualitative data are expressed as the number of tattoos, n (%). a No data on the timing of the tattoo procedure with respect to psoriasis onset or on the 
treatment received were available for 16 patients. b during follow-up
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Table 6. The frequency of local complications associated with tattoos according to treatment type
Treatments received in the psoriasis with treatment 
group N=198
Local treatments
n=72
Systemic 
treatments a
n=56
Biotherapies
n=67 P-value
Local complications b 5 (6.9) 8 (14.3) 15 (22.4) 0.03
Oedema 1 (1.4) 2 (3.6) 6 (9.0) 0.11
Isolated pruritus 4 (5.6) 2 (3.6) 8 (11.9) 0.19
Allergy 0 (0) 1 (1.8) 1 (1.5) -
Local infection 0 (0) 1 (1.8) 1 (1.5) -
Koebner phenomenon (Fig. 2) 3 (4.2) 6 (10.7) 9 (13.4) 0.15
Psoriasis flare after tattoo
Cutaneous psoriasis 7 (9.7) 4 (7.1) 4 (6.0) 0.75
Psoriatic arthritis 0 0 0
Presence of psoriasis plaques within the 
tattoo during a flare of the disease c
Psoriatic plaques within the tattoo (Fig. 3) 18 (25.0) 17 (30.4) 23 (34.3) 0.48
Tattoos spared by psoriasis 36 (50.0) 20 (35.7) 24 (35.8) 0.15
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Qualitative data are expressed as the number of tattoos n (%). a systemic treatments including phototherapy. b n (%) of tattoos associated with at least 
one complication. One tattoo may have been associated with multiple complications. c during follow-up
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Figure 1. Percentage of tattooed psoriatic patients according to age and gender
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Figure 2. Koebner phenomenon with psoriasis predominantly within a red tattoo. This aspect was 
later after tattooing, during a flare of the disease.
Figure 3. Plaque psoriasis on a tattoo (without Koebner phenomenon)
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